ChatGPT Distribution Undercuts OpenEvidence

This turns distribution into OpenAI’s biggest weapon. ChatGPT for Clinicians did not need to teach doctors a new behavior, because many physicians were already using ChatGPT for clinical questions, and OpenAI launched a free clinician specific workspace under the same login they already used. That is the classic bottom up motion, a free tool, instant access, individual usage first, and enterprise expansion later.1 2 3

• OpenEvidence proved the playbook first. By being free and avoiding patient records early, it spread doctor by doctor instead of waiting on hospital procurement, reaching 40% of U.S. physicians by mid 2025 and 65%+ monthly active usage by 2026 before pushing deeper into EHR and workflow products.4 1
• OpenAI can copy the motion with much larger top of funnel. ChatGPT for Clinicians launched on April 22, 2026 for verified U.S. clinicians, and the same account can be upgraded into a clinician workspace, which removes onboarding friction and lets OpenAI recruit from its existing habit base.2 3
• That makes OpenEvidence’s moat less about the chat box and more about what sits behind it. Its official partnerships with NEJM, JAMA, NCCN, Nature, and Cochrane, plus tools tied to documentation, coding, prescribing, and patient calls, matter because those are harder to clone than a free entry point.1 5

The next phase is a land grab for the daily doctor workflow. General models can win first touch because they already own user attention, but the durable winners in clinical AI will be the products that turn search into action inside care delivery, where proprietary medical content and workflow integrations make switching harder.1 4 5